

Monoclonal Antibodies against COVID-19

Tuesday 29th November 2022 6.30pm | Hilton Kuala Lumpur

AstraZeneca, is pleased to invite you to join leading international healthcare expert to explore solutions to the COVID-19 pandemic. We will have a comprehensive presentation and discussion on the unmet need for COVID-19 antibody based therapies, the latest scientific data on AZD7442, as well as, the role for antibody based therapies in a vaccine landscape.

Meet the Faculty



Prof Richard Hobbs

Nuffield Professor of Primary Care, Head of the Nuffield Department of Primary Care Health Sciences, Director of the Institute for Applied Digital Health, University of Oxford

He has served on many national and international scientific and research funding boards in U.K., Ireland Canada and WHO.

United Kingdom

The Agenda

Time	Duration	Agenda item	Presenter
6.30pm - 6.35pm	5 min	Welcome and introductions	Dr. Nadira Azmi AstraZeneca
6.35pm - 7.05pm	30 min	Monoclonal Antibodies against COVID-19	Prof. Richard Hobbs
7.05pm - 7.25pm	20 min	Q & A	Prof. Richard Hobbs Moderator: Dr. Nadira Azmi AstraZeneca
7.25pm - 7.30pm	5 min	Closing Remarks	Dr. Nadira Azmi AstraZeneca
7.30pm		Dinner	

This non-promotional scientific exchange meeting is organised and funded by AstraZeneca. For registered healthcare professionals only. This meeting focuses on the field of infectious diseases and monoclonal antibodies. RSVP is required. Please contact Nadira Azmi (010-9332823) or Jason Lew (016-2114452).

For healthcare professionals who would like to join us virtually, Zoom invitation will be provided after registration.

No Pendaftaran PPM-034-10-18062020



Persatuan Kawalan Infeksi & Penyakit Berjangkit Malaysia Malaysian Society of Infection Control & Infectious Diseases AstraZeneca 2